WO2023122317A3 - SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF - Google Patents

SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF Download PDF

Info

Publication number
WO2023122317A3
WO2023122317A3 PCT/US2022/053896 US2022053896W WO2023122317A3 WO 2023122317 A3 WO2023122317 A3 WO 2023122317A3 US 2022053896 W US2022053896 W US 2022053896W WO 2023122317 A3 WO2023122317 A3 WO 2023122317A3
Authority
WO
WIPO (PCT)
Prior art keywords
catenin
sina
molecules
nucleic acid
short interfering
Prior art date
Application number
PCT/US2022/053896
Other languages
French (fr)
Other versions
WO2023122317A2 (en
Inventor
Leonid Beigelman
Laxman Eltepu
Jin Hong
Aneerban BHATTACHARYA
Saul MARTINEZ MONTERO
Vera HUANG
Original Assignee
Aligos Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics, Inc. filed Critical Aligos Therapeutics, Inc.
Publication of WO2023122317A2 publication Critical patent/WO2023122317A2/en
Publication of WO2023122317A3 publication Critical patent/WO2023122317A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is in the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides that target β-catenin, compositions containing the same, and uses thereof for treating or preventing diseases. In particular, the present invention is in the field of siNA molecules that targets β-catenin for treatment of cancer.
PCT/US2022/053896 2021-12-23 2022-12-22 SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF WO2023122317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293553P 2021-12-23 2021-12-23
US63/293,553 2021-12-23

Publications (2)

Publication Number Publication Date
WO2023122317A2 WO2023122317A2 (en) 2023-06-29
WO2023122317A3 true WO2023122317A3 (en) 2023-08-03

Family

ID=85172661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/053896 WO2023122317A2 (en) 2021-12-23 2022-12-22 SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF

Country Status (1)

Country Link
WO (1) WO2023122317A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018754A2 (en) * 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2014065849A1 (en) * 2012-10-25 2014-05-01 Phaserx, Inc. Rna targeted to beta catenin
WO2017173297A1 (en) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
WO2019079472A1 (en) * 2017-10-18 2019-04-25 Dicerna Pharmaceuticals, Inc. Beta catenin nucleic acid inhibitor molecule
WO2021178885A1 (en) * 2020-03-06 2021-09-10 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
WO2021252557A1 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
WO2023003995A1 (en) * 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018754A2 (en) * 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2014065849A1 (en) * 2012-10-25 2014-05-01 Phaserx, Inc. Rna targeted to beta catenin
WO2017173297A1 (en) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
WO2019079472A1 (en) * 2017-10-18 2019-04-25 Dicerna Pharmaceuticals, Inc. Beta catenin nucleic acid inhibitor molecule
WO2021178885A1 (en) * 2020-03-06 2021-09-10 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
WO2021252557A1 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
WO2023003995A1 (en) * 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON BROOKE A ET AL: "Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides", NUCLEIC ACIDS RESEARCH, vol. 49, no. 16, 20 August 2021 (2021-08-20), GB, pages 9026 - 9041, XP093036509, ISSN: 0305-1048, Retrieved from the Internet <URL:https://watermark.silverchair.com/gkab718.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtYwggLSBgkqhkiG9w0BBwagggLDMIICvwIBADCCArgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM-A0MsthJORb0IJH8AgEQgIICiYQnekl9YNnEFTQL7lSubpCXfeHMc_RFWulASJclVelh-zCI3ZFmRZf0xxEZhYl-bXHhmHwjBsvbk6OOVXvDFl1iukuU> DOI: 10.1093/nar/gkab718 *
YU FANYUAN ET AL: "Wnt/[beta]-catenin signaling in cancers and targeted therapies", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 6, no. 1, 30 August 2021 (2021-08-30), XP055863867, Retrieved from the Internet <URL:https://www.nature.com/articles/s41392-021-00701-5.pdf> DOI: 10.1038/s41392-021-00701-5 *

Also Published As

Publication number Publication date
WO2023122317A2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JOP20210154B1 (en) Kif18a inhibitors
MX2021007104A (en) Kif18a inhibitors.
US11912994B2 (en) Methods for reactivating genes on the inactive X chromosome
Cheng et al. Paris saponin VII suppresses osteosarcoma cell migration and invasion by inhibiting MMP‑2/9 production via the p38 MAPK signaling pathway
BR112021019793A2 (en) Compositions and methods for inhibiting gene expression in the central nervous system
MX2007008065A (en) Compositions and methods for modulating gene expression using self-protected oligonucleotides.
Vitkeviciene et al. Epigallocatechin-3-gallate and BIX-01294 have different impact on epigenetics and senescence modulation in acute and chronic myeloid leukemia cells
Rodriguez-Ruiz et al. Potential of aqueous extract of saffron (Crocus sativus L.) in blocking the oxidative stress by modulation of signal transduction in human vascular endothelial cells
Griffin et al. Inhibiting mevalonate pathway enzymes increases stromal cell resilience to a cholesterol-dependent cytolysin
Abhishek et al. Leishmania donovani induced Unfolded Protein Response delays host cell apoptosis in PERK dependent manner
Li et al. USP21 regulates Hippo signaling to promote radioresistance by deubiquitinating FOXM1 in cervical cancer
WO2019217397A3 (en) Compositions and methods for improving strand biased
BR112023016614A2 (en) TYK2 INHIBITORS AND USES THEREOF
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
Faillace et al. Inhibition of the NorA efflux pump of S. aureus by (Z)-5-(4-Fluorobenzylidene)-Imidazolidines
Lee et al. Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53
WO2023122317A3 (en) SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
Lee et al. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib
Yam et al. Auranofin inhibits virulence pathways in Pseudomonas aeruginosa
WO2023122316A3 (en) SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
Ryu et al. Suberoylanilide hydroxamic acid can re-sensitize a cisplatin-resistant human bladder cancer
EP1618189A4 (en) Rnai agents for anti-sars coronavirus therapy
WO2022144882A3 (en) P21 mrna target areas for silencing
Arda et al. Stress-induced miRNAs isolated from wheat have a unique therapeutic potential in ultraviolet-stressed human keratinocyte cells
Geetika et al. Pulmonary expression of MYCN mRNA following exposure to 2, 4-D with or without endotoxin challenge

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22854300

Country of ref document: EP

Kind code of ref document: A2